Compare
AbbVie vs Gilead Sciences (ABBV vs GILD)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Gilead Sciences (GILD) +36.1%; so far this year the figures are +27.5% and +36.0%.
AbbVie is the larger company by market value, about 2.5 times the size of Gilead Sciences.
Revenue grew +10.7% at ABBV and +6.5% at GILD over the last year.
ABBV yields 2.38%. GILD yields 1.95%.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | GILD | |
|---|---|---|
| Price | $291.31 | $166.89 |
| 1-day | +1.07% | -0.41% |
| YTD | +27.49% | +35.97% |
| 1 year | +34.39% | +36.15% |
| 3 years | +104.47% | +108.12% |
| Market cap | $514.9B | $207.0B |
| P/E | 50.1 | — |
| P/S | 7.80 | 6.68 |
| P/B | — | 15.87 |
| Revenue growth | +10.70% | +6.50% |
| EPS growth | +340.20% | -149.00% |
| Gross margin % | 73.7 | 79.9 |
| Net margin % | 15.7 | -12.5 |
| ROE % | — | -29.6 |
| Debt / equity | — | 2.01 |
| FCF yield % | 3.7 | 6.7 |
| Dividend yield % | 2.38 | 1.95 |
| Beta | -0.03 | 0.37 |
| RSI (14) | 59.7 | 60.2 |
| Technical rating |